The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
Abstract
Purpose: To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non–small-cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patients and Methods: We designed a phase II study to test gefitinib antitumor efficacy in advanced-stage, chemotherapy-naive NSCLC patients. Patients were treated with gefitinib 250 mg/d. Tumor assessments were performed every 2 months. Responding or stable patients were treated until progression or unacceptable toxicity. All scans were reviewed independently. EGFR exons 18-21 sequence, K-ras exon 2 sequence, and MET gene copy numbers were examined in available samples. Clinical or molecular predictors of TTF were examined by multivariate analysis. Results: One hundred six patients were enrolled. Ninety patients had tumor samples for biomarker tests. Overall response rate was 50.9% (95% CI, 41.4% to 60.4%). Median TTF was 5.5 months, and median overall survival (OS) was 22.4 months. The response rate and median TTF of the patients with exon 19 deletion (n = 20) were 95.0% and 8.9 months, for exon 21 L858R mutation (n = 23) were 73.9% and 9.1 month, and for other types of EGFR mutations (N = 12) were 16.7% and 2.3 months, respectively. In multivariate analysis, the presence of EGFR deletion exon 19 or L858R EGFR mutations in adenocarcinoma patients predicted longer TTF. High copy number of MET seemed to correlate with shorter TTF in patients with gefitinib-sensitive activating EGFR mutations. Conclusion: In this prospective study, EGFR exon 19 deletion or L858R mutations in adenocarcinoma were the best predictors for longer TTF in stage IIIB/IV chemotherapy-naive NSCLC patients receiving first-line gefitinib monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Self-citationSutani, A., Nagai, Y., Udagawa, K., Uchida, Y., Koyama, N., Murayama, Y., Tanaka, T., Miyazawa, H., Nagata, M., Kanazawa, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603466 · Cited by 167
Research works printed but not linked: 32
- 10.1016/S1556-0864(15)30415-9 · DOI · Paper page
- 10.1200/JCO.2003.10.038 · DOI · Paper page
- 10.1200/JCO.2006.06.3958 · DOI · Paper page
- 10.1056/NEJMoa050736 · DOI · Paper page
- 10.1002/cncr.22220 · DOI
- 10.1158/1078-0432.CCR-04-2149 · DOI
- Lange T, Muller-Tidow C, Serve H, et al: First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. Oncol Rep 14:1539,2005-1542, · doi:10.3892/or.14.6.1539
- 10.1038/sj.bjc.6603393 · DOI · Paper page
- 10.1200/JCO.2005.02.5825 · DOI · Paper page
- 10.1038/sj.bjc.6603159 · DOI
- 10.1016/S1556-0864(15)31577-X · DOI
- 10.1016/j.lungcan.2006.07.013 · DOI
- 10.1073/pnas.0405220101 · DOI · Paper page
- 10.1200/JCO.2005.01.388 · DOI · Paper page
- 10.1200/JCO.2005.09.985 · DOI · Paper page
- 10.1200/JCO.2005.00.992 · DOI · Paper page
- 10.1002/ijc.21458 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-1951 · DOI · Paper page
- 10.1371/journal.pmed.0020017 · DOI · Paper page
- Yang CH, Yu CJ, Chen KY, et al: A phase II study of gefitinib as first line treatment for good performance advanced or metastatic non–small-cell lung cancer in East Asian patients. J Clin Oncol 24:405s,2006, (suppl; abstr 7167) · doi:10.1200/jco.2006.24.18_suppl.7167
- 10.1016/S1556-0864(15)30013-7 · DOI · Paper page
- 10.1016/j.lungcan.2007.01.025 · DOI
- 10.1200/JCO.2005.05.4692 · DOI · Paper page
- 10.1200/JCO.2006.07.3585 · DOI · Paper page
- 10.1016/S0012-3692(15)52173-9 · DOI
- 10.1002/jcb.10239 · doi:10.1002/jcb.10239
- 10.1093/jnci/dji112 · DOI · Paper page
- 10.1002/cncr.22593 · DOI
- 10.1200/JCO.2005.02.7078 · DOI · Paper page
- 10.1200/JCO.2005.02.857 · DOI · Paper page
- 10.1016/j.lungcan.2007.06.024 · DOI
- 10.1158/1078-0432.CCR-05-2324 · DOI · Paper page
Cited by
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationFukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
“A small proportion (1–20%, depending on the trial) of patients with no detectable EGFR -activating mutations show a radiographic response when treated with EGFR TKI”
BackgroundSelf-citationYang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002
Self-citation
Metadata
- Authors
- Yang, C.-H., Yu, C.-J., Shih, J.-Y., Chang, Y.-C., Hu, F.-C., Tsai, M.-C., Chen, K.-Y., Lin, Z.-Z., Huang, C.-J., Shun, C.-T., Huang, C.-L., Bean, J., Cheng, A.-L., Pao, W., & Yang, P.-C.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-06-01
- Volume
- 26
- Issue
- 16
- Pages
- 2745-2753
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2130254323
- Cited by
- 235
- References
- 9
- FWCI
- 25.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. https://app.cochat.ai/papers/10.1200/jco.2007.15.6695
- The paper
- Yang, C.-H., Yu, C.-J., Shih, J.-Y., Chang, Y.-C., Hu, F.-C., Tsai, M.-C., Chen, K.-Y., Lin, Z.-Z., Huang, C.-J., Shun, C.-T., Huang, C.-L., Bean, J., Cheng, A.-L., Pao, W., & Yang, P.-C. (2008). Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.6695
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.